CoChat

Alprazolam absorption kinetics affects abuse liability

Mumford, Geoffrey K., Evans, Suzette M., Fleishaker, Joseph C., Griffiths, Roland R. · 1995 · Clinical Pharmacology & Therapeutics

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the behavioral, subjective, and reinforcing effects of immediate-release (IR) alprazolam and extended-release (XR) alprazolam to assess the effect of release rate on laboratory measures of abuse liability. METHODS: Fourteen healthy men with histories of sedative abuse participated as subjects in a double-blind crossover study. All subjects received placebo, 1 and 2 mg immediate-release alprazolam, and 2 and 3 mg extended-release alprazolam in random order. Behavioral performance, subjective effects, and alprazolam plasma concentrations were assessed repeatedly 1/2 hour before and 1/2, 1, 3, 5, 7, 9, 12, and 24 hours after drug administration. RESULTS: Mean peak alprazolam plasma concentrations occurred 1.7 and 9.2 hours after immediate-release alprazolam and extended-release alprazolam, respectively. Compared to placebo, 2 mg immediate-release alprazolam impaired all measures of psychomotor and cognitive performance (Digit Symbol Substitution Test), motor coordination (circular lights and balance), and memory (digit entry and recall); 2 mg extended-release alprazolam did not affect any of these measures and 3 mg extended-release alprazolam impaired circular lights only. Immediate-release alprazolam, 2 mg, increased all six measures of positive drug effects (e.g., ratings of liking or good effects); none of these measures were increased by 2 mg extended-release alprazolam and only three of the six measures were increased by 3 mg extended-release alprazolam. A drug versus money multiple-choice procedure designed to assess the relative reinforcing effects of each condition was administered 24 hour after the drug. The amount of money subjects were willing to "pay" to take the drug was significantly greater than placebo for both doses of immediate-release alprazolam but for neither dose of extended-release alprazolam. CONCLUSIONS: These data indicate that extended-release alprazolam has less potential for abuse than immediate-release alprazolam.

Overview

Integrity signals

Registry

Crossref · 10.1016/0009-9236(95)90162-0

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 11

  1. Fischman M. W., 1984, Fed Proc, 43, 570
  2. Griffiths R. R., 1984, J Pharmacol Exp Ther, 229, 501
  3. Sellers E. M., 1993, J Clin Psychiatry, 54, 64
  4. Ciraulo D. A., 1988, J Clin Psychiatry, 49, 333
  5. Guarino J. J., 1988, Pharmacologist, 30, A196
  6. Wright C. E., 1991, Pharm Res, 10, S250
  7. Griffiths R. R., 1979, J Pharmacol Exp Ther, 210, 301
  8. Griffiths R. R., 1980, J Pharmacol Exp Ther, 215, 649
  9. Roache J. D., 1985, J Pharmacol Exp Ther, 234, 120
  10. Roache J. D., 1987, J Pharmacol Exp Ther, 243, 978
  11. Evans S. M., 1990, J Pharmacol Exp Ther, 255, 1246

Cited by

See all 63

Metadata

Authors
Mumford, G. K., Evans, S. M., Fleishaker, J. C., & Griffiths, R. R.
Affiliations
Johns Hopkins University (US)
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
1995-03
Volume
57
Issue
3
Pages
356-365
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2047501424
Cited by
63
References
30
Citations by year
2024: 2 · 2023: 3 · 2020: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2012: 7
FWCI
3.10
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse (DA03889, R01DA003889)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
alprazolam, sustained-release formulation, immediate-release formulation, drug release rate, abuse liability, sedative abuse, plasma drug concentration, psychomotor performance, cognitive performance, subjective drug effects, drug reinforcement
MeSH terms
Adult, Alprazolam, Analysis of Variance, Cognition, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Male, Psychomotor Performance, Surveys and Questionnaires, Reference Values, Time Factors, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alprazolam absorption kinetics affects abuse liability. https://app.cochat.ai/papers/10.1016/0009-9236(95)90162-0
The paper
Mumford, G. K., Evans, S. M., Fleishaker, J. C., & Griffiths, R. R. (1995). Alprazolam absorption kinetics affects abuse liability. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/0009-9236(95)90162-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.